EGFR and neoplasm: One step ahead, conjugation of EGFR antibody to sgPLK1–cLNPs caused their selective uptake into disseminated ovarian tumors, enabling ≈80% gene editing, significantly inhibited tumor growth, and enhanced survival by 80% following intraperitoneal injection in vivo.[79] Qui et al.